Status:
COMPLETED
Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention
Lead Sponsor:
Onassis Cardiac Surgery Centre
Conditions:
Renal Insufficiency, Chronic
Coronary Angiography
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
PHASE3
Brief Summary
The prevention of contrast-mediated nephropathy (CMN), which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast induced renal vasoconstriction is believed to play a ...
Eligibility Criteria
Inclusion
- Patients undergoing clinically driven, non-emergent coronary angiography or intervention in our institution were eligible for inclusion if their serum creatinine concentration was ≥1.4 mg/dl (124 μmol/l) and/or their creatinine clearance was \<60 ml/min on their most recent sample drawn within 1 month of the planned procedure
Exclusion
- Circulatory shock for any reason, systolic blood pressure \<95 mm Hg
- Known acute renal failure
- End-stage renal disease requiring dialysis
- Intravascular administration of a contrast medium within the previous 10 days
- Anticipated re-administration of contrast medium within the following 6 days
- Inability to administer intravenous hydration at least 4 h before the procedure or study medication at least 30 min before the procedure
- Primary intervention for acute infarction with ST elevation
- A procedure performed within 2 h of acute hospital admission
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT00345501
Start Date
November 1 2005
End Date
July 1 2007
Last Update
August 24 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Onassis Cardiac Surgery Centre
Athens, Greece, 17674